Search research articles
Contact Us
Filters
Showing results (1-10 of 927) with videos related to
Page
of 93
Sort By:
Gastroenterology
|
November 16, 2005
Of mice and men: what to learn about human inflammatory bowel disease from genetic analysis of murine inflammation
Stefan Schreiber
Gastroenterology & Hepatology
|
May 7, 2014
Commentary: vedolizumab: a new mechanism of action for the treatment of ulcerative colitis
Stefan Schreiber
Zeitschrift Fur Gastroenterologie
|
March 31, 2015
[Statement of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) for teduglutide-benefit assessment according to § 35a SGB V the G-BA]
Stefan Schreiber
Expert Review of Gastroenterology & Hepatology
|
September 24, 2015
An update on biosimilar drugs for inflammatory bowel disease
Stefan Schreiber
Therapeutic Advances in Gastroenterology
|
November 2, 2011
Certolizumab pegol for the treatment of Crohn's disease
Stefan Schreiber
Gastroenterology
|
May 9, 2009
The genetic universe of inflammatory bowel disease
Stefan Schreiber
Journal of Crohn'S & Colitis
|
February 11, 2020
Lack of Efficacy in Crohn's Disease Prompts Unplanned Interim Analysis and Termination of Study in Ulcerative Colitis
Stefan Schreiber
Drug Research
|
November 17, 2021
Stefan Schreiber
Gastroenterology
|
March 29, 2016
How Failure Can Fuel Improvements in Early Drug Development for Inflammatory Bowel Diseases
Stefan Schreiber, Séverine Vermeire
European Journal of Gastroenterology & Hepatology
|
May 10, 2008
Expression signatures, barriers and beyond: the role of oxidative stress in murine colitis and human inflammatory bowel disease revisited
Philip Rosenstiel, Stefan Schreiber
Page
of 93
Search research articles
Search
Showing results (1-10 of 927) with videos related to
Sort By:
Page
of 93
Gastroenterology
|
November 16, 2005
Of mice and men: what to learn about human inflammatory bowel disease from genetic analysis of murine inflammation
Stefan Schreiber
Gastroenterology & Hepatology
|
May 7, 2014
Commentary: vedolizumab: a new mechanism of action for the treatment of ulcerative colitis
Stefan Schreiber
Zeitschrift Fur Gastroenterologie
|
March 31, 2015
[Statement of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) for teduglutide-benefit assessment according to § 35a SGB V the G-BA]
Stefan Schreiber
Expert Review of Gastroenterology & Hepatology
|
September 24, 2015
An update on biosimilar drugs for inflammatory bowel disease
Stefan Schreiber
Therapeutic Advances in Gastroenterology
|
November 2, 2011
Certolizumab pegol for the treatment of Crohn's disease
Stefan Schreiber
Gastroenterology
|
May 9, 2009
The genetic universe of inflammatory bowel disease
Stefan Schreiber
Journal of Crohn'S & Colitis
|
February 11, 2020
Lack of Efficacy in Crohn's Disease Prompts Unplanned Interim Analysis and Termination of Study in Ulcerative Colitis
Stefan Schreiber
Drug Research
|
November 17, 2021
Stefan Schreiber
Gastroenterology
|
March 29, 2016
How Failure Can Fuel Improvements in Early Drug Development for Inflammatory Bowel Diseases
Stefan Schreiber, Séverine Vermeire
European Journal of Gastroenterology & Hepatology
|
May 10, 2008
Expression signatures, barriers and beyond: the role of oxidative stress in murine colitis and human inflammatory bowel disease revisited
Philip Rosenstiel, Stefan Schreiber
Page
of 93